论文部分内容阅读
目的评价莫沙比利治疗糖尿病神经源性膀胱疾病的疗效。方法 60例神经源性膀胱患者分为对照组和观察组。对照组:弥可保注射液。观察组:弥可保+莫沙比利。结果观察组总有效率为90.00%(27/30)高于对照组总有效率66.67%(20/30),差异具有显著性(P<0.05)。两组患者治疗后周围神经感觉传导速度明显改善,与治疗前比较差异显著(P<0.05)。治疗后,观察组周围神经感觉传导速度改善情况优于对照组,组间比较差异显著(P<0.01)。结论莫沙比利用于糖尿病神经源性膀胱患者疗效佳,值得临床推广应用。
Objective To evaluate the efficacy of mosapride in the treatment of diabetic neurogenic bladder disease. Methods Sixty patients with neurogenic bladder were divided into control group and observation group. Control group: Mi Kebao injection. Observation group: Miconus + Mosapride. Results The total effective rate was 90.00% (27/30) in the observation group and 66.67% (20/30) in the control group, with significant difference (P <0.05). Peripheral nerve sensory conduction velocity was significantly improved after treatment in both groups, which was significantly different from that before treatment (P <0.05). After treatment, the improvement of peripheral nerve sensory conduction velocity in the observation group was better than that in the control group, with significant difference between the two groups (P <0.01). Conclusion Mosapride is effective in patients with diabetic neurogenic bladder and is worthy of clinical application.